RecruitingPhase 1NCT04884035
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- CC-220(drug)
- Enrollment
- 224 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- Mayo Clinic - Arizona, Scottsdale, Arizona, United States
- Local Institution - 169, Duarte, California, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Mayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States
- University Of Kansas Medical Center, Kansas City, Kansas, United States
- Cancer Center Of Kansas-Wichita, Wichita, Kansas, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- HealthPartners Cancer Research Center, Saint Louis Park, Minnesota, United States
- University of Nebraska - Fred and Pamela Buffet Center, Omaha, Nebraska, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Local Institution - 170, Charlotte, North Carolina, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Local Institution - 168, Murray, Utah, United States
- Local Institution - 171, St. George, Utah, United States
- Local Institution - 501, Adelaide, South Australia, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04884035 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha